Copeptin Concentration Measured in Plasma Samples and Intradialytic Blood Pressure Variation

Condition(s) studied

Investigational drug(s) / intervention(s)

Routine biology samples et blood pressure mesures: Copeptin concentration will be measured from routine plasma samples, and blood pressure values will be recorded before, during, and after hemodialysis sessions using standard clinical monitoring. The primary outcome is the association between copeptin levels and intradialytic blood pressure variation.

Study summary

Vasopressin is a key regulator of water and vascular homeostasis, acting through V2 receptors to control renal water reabsorption and through V1a receptors to influence vascular tone. Copeptin, a stable surrogate marker of vasopressin release, provides a reliable measure of vasopressin activity. In hemodialysis, where ultrafiltration and osmotic shifts challenge fluid balance, the contribution of vasopressin to intradialytic blood pressure regulation remains uncertain. Elevated copeptin levels in dialysis patients have been associated with interdialytic weight gain and adverse cardiovascular outcomes. This study (CODIALHYP) tests the hypothesis that vasopressin activity, assessed through copeptin levels, is associated with intradialytic hypertension. The primary objective is to evaluate the relationship between copeptin concentrations and blood pressure changes during hemodialysis. Secondary objectives include assessing whether vasopressin's antidiuretic effect is preserved in hemodialysis patients and exploring the contribution of other hormonal pathways involved in fluid and vascular regulation.

Eligibility

Primary outcome measure(s)

• Copeptin Concentration Measured in Plasma Samples and Intradialytic Blood Pressure Variation — At baseline (M0) and at 3 months (M3), with copeptin measured at dialysis initiation (prehemodialysis) without additional blood sampling.
  Copeptin concentration will be measured from routine plasma samples, and blood pressure values will be recorded before, during, and after hemodialysis sessions using standard clinical monitoring. The primary outcome is the correlation between copeptin levels and intradialytic blood pressure variation.

Trial sites (1)

More Central Hospital, Nancy, France trials in France

Other trials for the same condition